In a 12-week study of 245 adults, Omada reports its members cut body fat percentage about twice as much as usual care. Results go to WOC 2026 in Boston.
Recap by typeshit. Full story at Yahoo Finance.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
A short item claims a newer group of weight loss drugs beats Ozempic, without naming the drugs or the data behind the claim.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
Labiotech walks through Novo Nordisk's 2026 pipeline and the new target it has set for risk-adjusted sales from drugs still in development.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
Loading…